Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1197720140070020067
´ëÇÑÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸÁö
2014 Volume.7 No. 2 p.67 ~ p.76
Maladaptive Reward-Learning and Impulse Control Disorders in Patients with Parkinson¡¯s Disease: A Clinical Overview and Pathophysiology Update
Lee Jee-Young

Jeon Beom-Seok
Abstract
Impulse control disorders (ICD) in Parkinson¡¯s disease (PD) are a disabling non-motor symptom with frequencies of 13?35% among patients receiving dopamine replacement therapy. ICD in PD is strongly associated with dopaminergic drug use, especially non-ergot dopamine agonists (DA). However, individual susceptibility and disease-related neural changes are also important contributors to the development of ICD. Discrepancies between nigrostriatal and mesolimbic dopaminergic degeneration and non-physiological administration of dopaminergic drugs may induce abnormal ¡¯hyperstimulation¡¯ of the mesolimbic system, which alters reward-learning behaviors in PD patients. In addition, DA can make patients more impulsive during decision-making and seek risk-taking behaviors. DA intake is also related to the biased representation of rewards. Ultimately, loss of negative feedback control due to dysfunctional frontostriatal connections is necessary for the establishment of ICD in PD. The subsequent behavioral and neural changes are affected by PD treatment and disease progression; thus, proper treatment guidelines for physicians are needed to prevent the development of ICD. Future studies aimed at producing novel therapeutics to control the risk factors for ICD or treat ICD behaviors in PD are warranted. This review summarizes recent advances from epidemiological and pathophysiological studies on ICD in PD. Management principles and limitations of current therapeutics are briefly discussed.
KEYWORD
Impulse control disorder, Parkinson¡¯s disease, Dopamine agonist, Reward-learning, Impulsivity, Addiction
FullTexts / Linksout information
 
Listed journal information